Clinical

Dataset Information

0

TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)


ABSTRACT: Liver metastases are a leading cause of death among patients with metastatic colorectal cancer. Duration of disease control is short following 2nd-line or later systemic therapy. Liver-directed therapy such as TACE has a higher response rate and improves progression-free survival (PFS), but the benefit is still limited. Cancer cells escape ischemic cell death via autophagy and hypoxia-inducible factor (HIF) activation. We hypothesize that blocking autophagy and the vascular endothelial growth factor (VEGF) pathway will improve both response and PFS following TACE.

DISEASE(S): Colorectal Neoplasms Malignant,Colorectal Cancer,Colorectal Neoplasms,Neoplasms

PROVIDER: 2376535 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2016-03-01 | E-GEOD-75048 | biostudies-arrayexpress
2016-05-13 | E-GEOD-77320 | biostudies-arrayexpress
2021-06-15 | GSE148351 | GEO
2022-01-24 | GSE125755 | GEO
2022-03-01 | GSE179016 | GEO
2016-02-11 | GSE77789 | GEO
2016-03-01 | GSE75048 | GEO
| S-EPMC2729124 | biostudies-other
2014-05-14 | E-GEOD-55915 | biostudies-arrayexpress
2021-11-03 | PXD007763 | Pride